Quest Diagnostics Receivables 2010-2025 | DGX

Quest Diagnostics receivables for the quarter ending March 31, 2025 were $1.404B, a 6.2% increase year-over-year.

  • Quest Diagnostics receivables for 2024 were $1.304B, a 7.77% increase from 2023.
  • Quest Diagnostics receivables for 2023 were $1.21B, a 1.26% increase from 2022.
  • Quest Diagnostics receivables for 2022 were $1.195B, a 16.9% decline from 2021.

Quest Diagnostics Receivables 2010-2025 | DGX

  • Quest Diagnostics receivables for 2024 were $1.304B, a 7.77% increase from 2023.
  • Quest Diagnostics receivables for 2023 were $1.21B, a 1.26% increase from 2022.
  • Quest Diagnostics receivables for 2022 were $1.195B, a 16.9% decline from 2021.
Related Stocks
Company NameMarket
Cap
DaVita (DVA)$11.2B
Encompass Health (EHC)$10.4B
Chemed (CHE)$8.5B
Option Care Health (OPCH)$5.3B
Elanco Animal Health (ELAN)$4.2B
RadNet (RDNT)$3.7B
Amedisys (AMED)$3B
LifeStance Health (LFST)$2.6B
Addus HomeCare (ADUS)$1.8B
Astrana Health (ASTH)$1.6B
U.S Physical Therapy (USPH)$1B
Pennant (PNTG)$907M
Aveanna Healthcare Holdings (AVAH)$886M
Atai Life Sciences (ATAI)$294M
Daxor (DXR)$36M
Ontrak (OTRK)$6M
MEDIROM Healthcare Technologies (MRM)$4M
Psychemedics (PMD)$0M